Clinical Trial Update: Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating lenalidomide as second-line therapy for advanced hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Liver Cancer | Phase 2 | Status: COMPLETED